Actinogen Medical Ltd has released a press release.
Significant Advance in Development of Alzheimers Drug
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- FDA Feedback on Xanamem Alzheimers Trail
- R&D Tax Rebate
- New Patents Allowed for B-HSD1 Inhibitor
- Further results in bio-ethanol test program
- Announcement of non-renounceable rights issue
Later from Actinogen Medical
- FDA Approval to Commence Alzheimers Disease Clinical Trial
- Appendix 4C - quarterly
- Xanamem Research Published in Prestigious Medical Journal
- UK Regulatory Approval for Alzheimers Clinical Trial-XanADu
- Actinogen Medical Financial Results
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical